Omnicell (NASDAQ:OMCL) Downgraded to “Hold” Rating by StockNews.com

StockNews.com cut shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a report released on Friday.

OMCL has been the subject of a number of other reports. Benchmark reiterated a “buy” rating and set a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Wells Fargo & Company raised their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Barclays lifted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. increased their target price on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Finally, Craig Hallum lifted their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $50.83.

Omnicell Trading Up 0.8 %

OMCL stock opened at $46.05 on Friday. The stock has a 50-day moving average price of $44.20 and a two-hundred day moving average price of $36.96. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74. The stock has a market cap of $2.13 billion, a PE ratio of -117.10, a price-to-earnings-growth ratio of 43.97 and a beta of 0.81.

Institutional Investors Weigh In On Omnicell

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Omnicell by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after acquiring an additional 80,312 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after purchasing an additional 508,789 shares during the period. Champlain Investment Partners LLC raised its holdings in shares of Omnicell by 16.0% in the 1st quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock valued at $51,246,000 after purchasing an additional 241,235 shares during the period. Dimensional Fund Advisors LP grew its holdings in Omnicell by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after purchasing an additional 3,570 shares during the period. Finally, Victory Capital Management Inc. grew its holdings in Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after purchasing an additional 1,138,921 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.